派斯双林生物制药股份有限公司股东股份解除质押及重新质押公告深度解读
要点概述
- 2026年7月25日，派斯双林生物制药股份有限公司（简称“派林生物”，证券代码：000403）发布公告，披露公司股东哈尔滨同智成科技开发有限公司（简称“同智成科技”）近期对其所持有公司的部分股份进行了解除质押及重新质押操作。
- 本次涉及股份数量较大，且质押用途为补充流动资金，这对于公司的资金结构及潜在经营流动性具有一定影响。
详细内容解读
一、解除质押及重新质押的基本情况
- 解除质押： 同智成科技于2026年7月21日解除质押26,000,000股，占其所持股份的24.88%、公司总股本的2.74%。该部分股份的质权人为李恒安。
- 重新质押： 随后，同智成科技于2026年7月23日将31,800,000股股份进行了重新质押，占其所持股份的30.43%、公司总股本的3.35%。质权人为中国银河证券股份有限公司，质押主要用于补充流动资金。质押将持续至办理解除质押登记手续之日。
二、股东股份累计质押情况
- 截至公告披露日，同智成科技及其一致行动人累计持有公司股份104,495,466股，占公司总股本的10.99%。
- 本次操作后，同智成科技处于质押状态的股份数量提升至47,630,000股，占其持股总数的45.58%，占公司总股本的5.01%。
- 其他大股东如横琴广金美好基金管理有限公司、美好海德薇一号私募证券投资基金、哈尔滨兰香生物技术咨询有限公司等目前并未有股份处于质押状态。
- 值得注意的是，杨莉持有的股份中有7,701,693股为未质押股份，但处于限售和冻结状态，占其持股的75%。
三、对公司及投资者的影响
- 公告明确表示，同智成科技及其一致行动人具备良好的资金偿还能力，当前质押股份暂无平仓或被强制过户的风险。
- 本次股份质押不涉及重大资产重组等业绩补偿义务，也不会对公司治理和经营管理造成重大影响。
- 但鉴于本次质押规模较大，且质押股份占同智成科技持股比例较高，若未来市场环境发生变化，或相关方资金链出现问题，依然可能对公司股价及股东结构带来潜在波动。
- 公司将持续关注相关质押股份的后续进展，并按规定及时披露，投资者应关注相关风险。
投资者须知及潜在影响
- 大股东高比例质押股权，虽然当前无强平风险，但一旦质权方要求补仓或市场波动，容易引发市场担忧，可能对股价产生一定压力。
- 质押用于“补充流动资金”，如果反映公司及相关股东存在一定流动性需求，需关注后续公司资金状况和经营表现。
- 后续如有解质或质押股份变动、控股权风险变化等事项，或将成为影响公司价值得失的关键变量。
备查文件
- 证券质押登记证明
- 中国证券登记结算有限责任公司股份冻结明细
结论
本次大股东大规模解除质押并重新质押，公司流动性需求提升，股东高比例质押股份，虽然当前无强平风险，但中长期需密切关注相关变动对公司股价及控股权结构可能带来的影响，投资者应保持关注并注意投资风险。
免责声明： 本文仅为信息披露公告的解读与分析，不构成任何投资建议。投资有风险，入市需谨慎。请以公司公告及相关法规为准。
English Version
Paling Biopharma Shareholder Share Pledge & Release Update: What Investors Need to Know
Key Highlights
- On July 25, 2026, Paling Biopharma (Ticker: 000403) announced that shareholder Harbin Tongzhicheng Technology Development Co., Ltd. (“Tongzhicheng Technology”) has recently released the pledge on a portion of its shares and re-pledged another portion.
- This involves a significant amount of shares, with the new pledge mainly aimed at supplementing working capital, which may affect the company’s capital structure and liquidity.
Details
1. Details of Share Pledge Release and Re-pledge
- Pledge Release: On July 21, 2026, Tongzhicheng Technology released the pledge on 26,000,000 shares, representing 24.88% of its holdings and 2.74% of the company’s total share capital. The pledgee was Li Heng’an.
- New Pledge: On July 23, 2026, Tongzhicheng Technology pledged 31,800,000 shares, accounting for 30.43% of its own holdings and 3.35% of the company’s total share capital, to China Galaxy Securities Co., Ltd. The purpose is to supplement liquidity. The pledge remains until the release procedures are completed.
2. Cumulative Share Pledge Status
- After the transaction, Tongzhicheng Technology and its concerted parties collectively hold 104,495,466 shares (10.99% of total shares).
- Pledged shares now total 47,630,000 (45.58% of their holdings, 5.01% of total share capital).
- Other major shareholders, such as Hengqin Guangjin Meihau Fund Management Co., Ltd., Meihau Hydewei No.1 Private Fund, and Harbin Lanxiang Biotech Consulting, do not currently have pledged shares.
- Notably, shareholder Yang Li has 7,701,693 shares (75% of her holdings) in a frozen or locked-up status, though not pledged.
3. Potential Impacts & Investor Considerations
- The company states that Tongzhicheng Technology and its affiliates have strong repayment ability and there is no risk of forced liquidation at this time.
- The pledge does not involve major asset restructuring or performance compensation obligations, nor is it expected to materially affect company governance or operations.
- However, given the high proportion of pledged shares, any adverse market developments or liquidity issues at the shareholder level could pose risks to share price and control structure.
- The company pledges to monitor and promptly disclose subsequent developments; investors should remain vigilant to potential risks.
Files for Reference
- Securities pledge registration certificate
- CSRC share freeze details
Conclusion
The significant release and re-pledge of shares by a major shareholder, and the increased proportion of pledged shares, though currently not at forced liquidation risk, is a dynamic investors should closely monitor for any changes in market or shareholder liquidity that could impact share price or control.
Disclaimer: This article is an analysis of company disclosures and does not constitute investment advice. Please refer to official company announcements and regulations. Investment carries risk. Proceed with caution.
